- Home
- ISRG vs AMGN Comparison
ISRG vs AMGN Comparison
Compare ISRG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | AMGN |
|---|---|---|
| Founded | 1995 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5B | 202.4B |
| IPO Year | 1998 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ISRG | AMGN |
|---|---|---|
| Price | $508.31 | $382.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 18 |
| Target Price | ★ $612.40 | $345.12 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.62% |
| EPS Growth | 22.59 | ★ 88.23 |
| EPS | 7.87 | ★ 14.23 |
| Revenue | $10,064,700,000.00 | ★ $25,424,000,000.00 |
| Revenue This Year | $16.75 | $4.88 |
| Revenue Next Year | $13.85 | $2.58 |
| P/E Ratio | $64.25 | ★ $26.99 |
| Revenue Growth | ★ 20.51 | 8.83 |
| 52 Week Low | $425.27 | $265.66 |
| 52 Week High | $603.88 | $387.49 |
Technical Indicators
Market Signals| Indicator | ISRG | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 63.71 |
| Support Level | $498.17 | $334.89 |
| Resistance Level | $557.45 | $385.12 |
| Average True Range (ATR) | 11.59 | 8.41 |
| MACD | 4.31 | 0.26 |
| Stochastic Oscillator | 96.24 | 74.29 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.